Literature DB >> 17550941

Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase.

Erica Scappini1, Tong-Wey Koh, Negin P Martin, John P O'Bryan.   

Abstract

Huntingon's disease is a progressive neurodegenerative disease arising from expansion of a polyglutamine (polyQ) tract in the protein huntingtin (Htt) resulting in aggregation of mutant Htt into nuclear and/or cytosolic inclusions in neurons. Mutant Htt affects multiple processes including protein degradation, transcription, signal transduction, fast axonal transport and endocytosis [reviewed in Ross, C.A. and Poirier, M.A. (2005) Opinion: what is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell. Biol., 6, 891-898]. Here, we report that the endocytic and signal transduction scaffold intersectin (ITSN) increased aggregate formation by mutant Htt through activation of the c-Jun-NH(2)-terminal kinase (JNK)-MAPK pathway. Conversely, silencing ITSN or inhibiting JNK attenuated aggregate formation. Using a Drosophila model for polyQ repeat disease, we observed that ITSN enhanced polyQ-mediated neurotoxicity. A reciprocal relationship was observed between ITSN and Htt. While ITSN enhanced Htt aggregation and toxicity, Htt, in turn, inhibited the cooperativity between ITSN and the epidermal growth factor receptor signal transduction pathway. Finally, we observed that ITSN overexpression enhanced aggregation of polyQ-expanded androgen receptor (AR) as well as wild-type versions of both Htt and AR suggesting a broader involvement of ITSN in neurodegenerative diseases through destabilization of polyQ-containing proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17550941     DOI: 10.1093/hmg/ddm134

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice.

Authors:  Nuria Suelves; Andrés Miguez; Saray López-Benito; Gerardo García-Díaz Barriga; Albert Giralt; Elena Alvarez-Periel; Juan Carlos Arévalo; Jordi Alberch; Silvia Ginés; Verónica Brito
Journal:  Mol Neurobiol       Date:  2018-05-27       Impact factor: 5.590

3.  A protein quality control pathway regulated by linear ubiquitination.

Authors:  Eva M van Well; Verian Bader; Maria Patra; Ana Sánchez-Vicente; Jens Meschede; Nikolas Furthmann; Cathrin Schnack; Alina Blusch; Joseph Longworth; Elisabeth Petrasch-Parwez; Kohji Mori; Thomas Arzberger; Dietrich Trümbach; Lena Angersbach; Cathrin Showkat; Dominik A Sehr; Lena A Berlemann; Petra Goldmann; Albrecht M Clement; Christian Behl; Andreas C Woerner; Carsten Saft; Wolfgang Wurst; Christian Haass; Gisa Ellrichmann; Ralf Gold; Gunnar Dittmar; Mark S Hipp; F Ulrich Hartl; Jörg Tatzelt; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2019-03-18       Impact factor: 11.598

Review 4.  Intersectin scaffold proteins and their role in cell signaling and endocytosis.

Authors:  Erika Herrero-Garcia; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-10-12       Impact factor: 4.739

5.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

Review 6.  Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis.

Authors:  Surendra S Ambegaokar; Bidisha Roy; George R Jackson
Journal:  Neurobiol Dis       Date:  2010-05-31       Impact factor: 5.996

7.  Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.

Authors:  Peter H Reinhart; Linda S Kaltenbach; Christian Essrich; Denise E Dunn; Joshua A Eudailey; C Todd DeMarco; Gregory J Turmel; Jennifer C Whaley; Andrew Wood; Seongeun Cho; Donald C Lo
Journal:  Neurobiol Dis       Date:  2011-03-31       Impact factor: 5.996

8.  Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome.

Authors:  Michael P Hunter; Marianela Nelson; Michael Kurzer; Xuerong Wang; Richard J Kryscio; Elizabeth Head; Graziano Pinna; John P O'Bryan
Journal:  Neuroreport       Date:  2011-10-26       Impact factor: 1.837

9.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

Review 10.  Intersectin 1: a molecular linker in the central nervous system.

Authors:  Ning Ma; Rui-Fang Niu; Yong-Jie Ma
Journal:  Neurosci Bull       Date:  2008-12       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.